
Janux Therapeutics Investor Relations Material
Latest events

Status Update
Janux Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Janux Therapeutics Inc
Access all reports
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer treatment. The company leverages its proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to create targeted therapies that activate the immune system specifically within the tumor microenvironment, minimizing systemic side effects. Janux Therapeutics is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Key slides for Janux Therapeutics Inc


Status Update
Janux Therapeutics Inc


Status Update
Janux Therapeutics Inc
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
JANX
Country
🇺🇸 United States